Search Results

This analysis examines monkeypox vaccine allocations and jurisdictional requests. It explores jurisdictional request rate (the number of vaccine does requested as a share of the jurisdiction’s allocation from HHS) for JYNNEOS, the preferred vaccine. Overall, while most jurisdictions have requested at least their full supply, some are well below that mark, raising questions about how quickly their at-risk populations can get protected.

This post provides updated estimates the number of people who are not up-to-date on COVID-19 vaccination living in counties designated by the CDC as being “high” or “medium” COVID-19 community levels. These are areas of elevated risk, with relatively high levels of new COVID-19 cases and strained hospital capacity. This analysis finds that the number of those not up to date on COVID-19 vaccination, and the most at risk for severe illness, living in areas of elevated risk has grown since early June 2022.

The brief provides a quick explainer of the prescription drug provisions in legislative text released by the Senate Finance Committee to be included in a forthcoming reconciliation bill and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.

A new report from KFF (Kaiser Family Foundation) and The Joint United Nations Programme on HIV/AIDS (UNAIDS) finds that donor governments disbursed US$7.5 billion in 2021 to combat HIV in low- and middle-income countries, largely flat amid the COVID-19 pandemic and essentially matching 2008 levels, against a backdrop of growing…

This report tracks funding levels of the donor governments that collectively provide the bulk of international assistance for AIDS through bilateral programs and contributions to multilateral organizations. Donor governments disbursed US$7.5 billion in 2021, largely flat amid the COVID-19 pandemic and essentially matching 2008 levels.

This brief answers key questions about the U.S. monkeypox outbreak to date and identifies issues that may affect the response going forward.

Most Parents Open to Getting Their Young Child Vaccinated Haven’t Yet Spoken to Their Pediatrician Most parents of young children newly eligible for a COVID-19 vaccine are reluctant to get them vaccinated, including 43% who say they will “definitely not” do so, a new KFF COVID-19 Vaccine Monitor survey finds…

In the wake of the FDA’s emergency use authorization for COVID-19 vaccines for children ages 6 months through 4 years old, many parents remain hesitant to vaccinate their children in this age group, with a slight majority saying they view the vaccine as a bigger risk to their child’s health than getting infected with coronavirus.

Children between the ages of 6 months and 5 years of age finally became eligible for COVID-19 vaccination in the U.S. on June 18, after the Director of the Centers for Disease Control and Prevention (CDC) recommended their use for this population, following emergency use authorization granted by the Food and Drug Administration. Here, we examine the status of vaccine uptake in this group, one month into their eligibility.

This analysis finds that the ACA’s maximum out-of-pocket limit is likely to grow faster than wages and salaries, and is also expected to grow faster than the maximum out-of-pocket limit for Health Savings Account (HSA)-qualified health plans.